Security
SCNX · Scienture Holdings, Inc.
SCNXNASDAQCommon stockCurrentCIK 1382574Updated Sep 27, 2026
Name history
TRxADE HEALTH, INC · through Aug 28, 2024TRXADE GROUP, INC. · through May 28, 2021XCELLINK INTERNATIONAL INC. · through Jan 31, 2014Bluebird Exploration Co. · through Dec 10, 2008
SCNX price & chart
Loading TradingView…
NASDAQ:SCNX on TradingView ↗About the company
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, including Scienture, LLC is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture, LLC are across therapeutics areas, indications and cater to different market segments and channels. For more information xplease visit www.scienture.com.
In the news
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement ↗
Recent filings
DEF 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
PRE 14A filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 84,178,330Source | 104,853,805Source | 12,532,913Source | 3,710,026Source |
| Property, Plant and Equipment, NetUSD | 15,500Source | 17,500Source | 277,009Source | 65,214Source |
| GoodwillUSD | — | 21,372,960Source | — | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 70,973,064Source | 76,400,000Source | 8,962,688Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,662,008Source | — | 151,908Source | 1,133,633Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 731,328Source | 11,106Source | 821,804Source | 728,964Source |
| Inventory, NetUSD | 213,408Source | — | 968Source | 119,582Source |
| Assets, CurrentUSD | 7,916,406Source | 6,305,477Source | 2,753,062Source | 2,093,123Source |
| Operating Lease, Right-of-Use AssetUSD | 23,360Source | 201,433Source | 529,623Source | 1,051,815Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 14,057,946Source | 25,781,684Source | 11,990,560Source | 3,367,159Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 406Source | 87Source | 9Source | 99Source |
| Additional Paid in CapitalUSD | 150,671,215Source | 118,111,007Source | 33,788,284Source | 20,482,573Source |
| Retained Earnings (Accumulated Deficit)USD | -80,551,237Source | -39,038,973Source | -33,245,940Source | -19,719,536Source |
| Stockholders' Equity Attributable to ParentUSD | 70,120,384Source | 79,072,121Source | 542,353Source | 763,136Source |
| Liabilities and EquityUSD | 84,178,330Source | 104,853,805Source | 12,532,913Source | 3,710,026Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,735,351Source | 7,906,893Source | 11,556,355Source | 2,146,791Source |
| Operating Lease, Liability, CurrentUSD | 24,137Source | 63,334Source | 139,705Source | 196,872Source |
| Accounts Payable, CurrentUSD | 1,443,266Source | 2,898,683Source | 2,082,054Source | 729,153Source |
| Operating Lease, Liability, NoncurrentUSD | — | 156,469Source | 409,205Source | — |
| Deferred Income Tax Liabilities, NetUSD | 11,037,595Source | 13,524,213Source | — | — |
| Other Liabilities, NoncurrentUSD | — | — | — | 887,035Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | -420,269Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 657,034Source | 1,313,731Source | 400,987Source | 290,013Source |
| Deferred Tax Liabilities, NetUSD | 16,052,838Source | 16,052,838Source | 143,430Source | — |
| Long-term DebtUSD | — | 2,897,698Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | 9,065,798Source | -17,843,574Source | -3,909,868Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,068,892Source | — | 29,738Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 720,222Source | 11,106Source | 293,784Source | -496,692Source |
| Increase (Decrease) in InventoriesUSD | 213,408Source | -968Source | -4,232,947Source | 63,303Source |
| Increase (Decrease) in Accounts PayableUSD | -1,567,215Source | 448,572Source | 1,607,625Source | 252,125Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,379,683Source | -14,265,239Source | — | -1,525,929Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 27,552,791Source | — | -427,845Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 12,000Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 19,733,595Source | -12,979,770Source | — | -35,171Source |
| Dividends paid | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 6,353,912Source | 307,782Source | -942,986Source | -1,988,945Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 733,694Source | 336,206Source |
| Additional Financial Items | ||||
| AmortizationUSD | — | — | 814,790Source | — |
| Amortization of Intangible AssetsUSD | 453,846Source | — | 814,790Source | 44,100Source |
| DepreciationUSD | 2,000Source | 2,000Source | 19,375Source | 14,637Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 2,296,834Source | 180,383Source | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | 4,100Source |
| Gain (Loss) on Disposition of AssetsUSD | — | -374,968Source | — | 4,100Source |
| General and Administrative ExpenseUSD | 7,926,016Source | 6,677,580Source | 2,785,633Source | 1,755,433Source |
| GoodwillUSD | — | 21,372,960Source | — | 0Source |
| Goodwill, Impairment LossUSD | 26,346,050Source | — | 5,129,115Source | 792,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | 792,500Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | -4,973,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -41,512,264Source | -18,244,480Source | -13,720,546Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -41,512,264Source | -18,244,480Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 27,310,278Source | -4,123,028Source | — |
| Income Tax Expense (Benefit)USD | -1,994,878Source | -534,396Source | — | — |
| InterestExpenseNonoperatingUSD | 4,083,206Source | 1,335,631Source | — | — |
| Inventory Write-downUSD | — | — | — | 875,250Source |
| Net Income (Loss) Attributable to ParentUSD | -41,512,264Source | 9,065,798Source | -17,843,574Source | -3,472,099Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | -437,769Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -3,472,099Source |
| Nonoperating Income (Expense)USD | -916,300Source | -4,077,861Source | -6,457,140Source | 514,427Source |
| Operating ExpensesUSD | 42,922,324Source | 14,707,020Source | 9,861,663Source | 9,875,511Source |
| Proceeds from Contributed CapitalUSD | — | — | — | 1,500,000Source |
| Proceeds from Issuance of Common StockUSD | 26,293,039Source | 2,954,000Source | — | 130,918Source |
| Proceeds from Stock Options ExercisedUSD | — | 9,840Source | — | — |
| Stock or Unit Option Plan ExpenseUSD | 307,439Source | 25,584Source | 29,738Source | 79,163Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 431,609Source | 136,643Source | 8,272,214Source | 11,448,265Source |
| Cost of RevenueUSD | 100,127Source | 130,638Source | 5,673,957Source | 5,997,049Source |
| Operating Income (Loss)USD | -42,590,842Source | -14,701,015Source | -7,263,406Source | -4,424,295Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -43,507,142Source | -18,778,876Source | — | — |
| Income Tax Expense (Benefit)USD | -1,994,878Source | -534,396Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | -437,769Source |
| Net Income (Loss) Attributable to ParentUSD | -41,512,264Source | 9,065,798Source | -17,843,574Source | -3,472,099Source |
| Earnings Per Share, BasicUSD per share | -2.7Source | 2.69Source | -23.35Source | -0.41Source |
| Earnings Per Share, DilutedUSD per share | -2.7Source | 2.48Source | -7.49Source | -0.41Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 15,347,312Source | 3,375,325Source | 764,058Source | 8,472,946Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 15,347,312Source | 3,653,609Source | 2,381,443Source | — |
| Interest Expense (non-operating)USD | 4,083,206Source | 1,335,631Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 453,846Source | — | 814,790Source | 44,100Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 491,781Source | — | — | — |
| General and Administrative ExpenseUSD | 7,926,016Source | 6,677,580Source | 2,785,633Source | 1,755,433Source |
| Goodwill, Impairment LossUSD | 26,346,050Source | — | 5,129,115Source | 792,000Source |
| Gross ProfitUSD | 331,482Source | 6,005Source | 2,598,257Source | 5,451,216Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -41,512,264Source | -18,244,480Source | -13,720,546Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -41,512,264Source | -18,244,480Source | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -2.7Source | -5.41Source | -17.96Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -2.7Source | -5.41Source | -5.76Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 27,310,278Source | -4,123,028Source | — |
| Interest ExpenseUSD | — | — | 1,198,346Source | 336,206Source |
| Interest Income, OtherUSD | 302,702Source | 135,337Source | 4,198Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -3,472,099Source |
| Nonoperating Income (Expense)USD | -916,300Source | -4,077,861Source | -6,457,140Source | 514,427Source |
| Operating ExpensesUSD | 42,922,324Source | 14,707,020Source | 9,861,663Source | 9,875,511Source |
| Research and Development ExpenseUSD | 1,956,270Source | 2,236,690Source | — | — |
Offerings
Registration 333-286399
Registration 333-283591
Filing attachments
ex99-1.htm · 8-K · 2026-08-20
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million Commenced Co…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-22
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) - SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distrib…
Read attachment ↗ex99-1.htm · 8-K · 2025-08-15
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) - Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreem…
Read attachment ↗